The DOI matches its Crossref record; 116 of the 117 references it cites were found in a registry or an index; 11 of the 134 sources its claims cite were checked for support.
Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes
Open accessAbstract
Glucose homeostasis is primarily maintained by pancreatic hormones, insulin and glucagon, with an emerging role for a third islet hormone, somatostatin, in regulating insulin and glucagon responses. Under healthy conditions, somatostatin secreted from pancreatic islet δ-cells inhibits both insulin and glucagon release through somatostatin receptor- induced cAMP-mediated downregulation and paracrine inhibition of β- and α-cells, respectively. Since glucagon is the body’s most important anti-hypoglycemic hormone, and because glucagon counterregulation to hypoglycemia is lost in diabetes, the study of somatostatin biology has led to new investigational medications now in development that may help to restore glucagon counterregulation in type 1 diabetes. This review highlights the normal regulatory role of pancreatic somatostatin signaling in healthy islet function and how the inhibition of somatostatin receptor signaling in pancreatic α-cells may restore normal glucagon counterregulation in diabetes mellitus.
Overview
CoChat Summary
## TL;DR
This review argues that excessive somatostatin receptor 2 (SSTR2) signaling may suppress counterregulatory glucagon release in type 1 diabetes and advanced type 2 diabetes, contributing to treatment-induced hypoglycemia. It summarizes non-clinical and early clinical evidence that SSTR2 antagonists can restore glucagon responses and reduce hypoglycemia risk.
## Key findings
- In animal models of T1D, the selective SSTR2 antagonist PRL-2903 normalized plasma glucagon and reduced hypoglycemia burden: in biobreeding rats it “fully alleviated” glucose infusion dependence during clamped hypoglycemia, and in STZ rats it reduced exogenous glucose dependence at low-dose insulin (5 U/kg) but not high-dose insulin (10 U/kg).
- In recurrently hypoglycemic STZ-T1D rats, PRL-2903 prevented a “20-fold reduction” in the plasma glucagon response after 5 antecedent hypoglycemic episodes in 3 days, raised the glucose nadir from 2.7 mmol/L to 3.7 mmol/L, and reduced time spent in hypoglycemia (≤3.9 mmol/L) by about 50 min.
- A more potent SSTR2 antagonist, ZT-01, outperformed PRL-2903 in STZ-T1D rats: peak plasma glucagon response was about 4-fold higher than with PRL-2903 during clamped hypoglycemia, and cumulative drug exposure (AUC) was 11 times higher over 24 h.
- In one phase 1b trial in adults with T1D, ZT-01 (3 or 20 mg) increased peak plasma glucagon by up to 15 pg/mL during level 1 hypoglycemia (3.5 ± 0.3 mmol/L), while placebo showed no response; during level 2 hypoglycemia (2.6 ± 0.2 mmol/L), the increase from baseline to peak glucagon was more than 3-fold higher with ZT-01 than placebo.
## Methods
- This is a narrative review, not an original experimental study; it compiles prior non-clinical and clinical evidence on SST/SSTR2 biology and SSTR2 antagonism in diabetes.
- It synthesizes findings from rodent models of T1D, pre-diabetes, and T2D, including STZ-induced diabetes, biobreeding rats, high-fat-fed models, and HFF/low-dose STZ models, plus early human phase 1/1b and phase 2 trial information.
- Main analyses described in the cited studies include clamped hypoglycemia, bolus insulin challenges, exercise-induced hypoglycemia, oral glucose tolerance tests, pancreas/islet perfusion, and comparisons of glucagon, glucose nadir, and time spent hypoglycemic.
## Limitations
- The paper states that the human and rodent data are still preliminary in several places; for example, the T2D islet findings “must be confirmed in larger samples,” and the phase 1b ZT-01 trial is described as a manuscript “not yet peer-reviewed.”
- It notes that only one published abstract had profiled in vivo SSTR2a effects in T2D at the time of writing, so evidence for late-stage T2D remains limited.
- Evident from the text: because this is a review, it does not present a single unified study design, and the included studies vary in model, dose, route, and hypoglycemia induction method, which the authors themselves say may explain variability in responses.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
10 Valid · 2 Not valid · 85 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Mathematical modeling of δ-cells suggests that hyperpolarizing (inhibitory) membrane currents spread from β-cells to δ-cells via gap junction connections under low glucose conditions (≤3.9 mmol/L), in turn, suppressing δ-cell activity and SST release ( Briant et al., 2018 ; Miranda et al., 2022 ).”
What the sources say
- Disputedcites Briant et al., 2018 sourceExperimental — accuracy not yet measured
Our copy states the opposite mechanism and condition: the Discussion (Fig. 9 schematic) says that in HIGH glucose β-cell depolarization 'drives cation flow through gap junctions (GJ) with coupled δ-cell(s)', depolarizing the δ-cell and thereby DRIVING somatostatin secretion, which then hyperpolarizes α-cells via SSTR2/GIRK. The Results (Simulation of human islets, Fig. 7) likewise report that 'Application of high glucose generated bursting in β-cells, which triggered action potential firing in a neighbouring δ-cell via the GJs and evoked somatostatin secretion', while 'In low glucose, only the α-cells were electrically active' — no hyperpolarizing β-to-δ current or δ-cell/SST suppression is modelled or claimed at low glucose. The claim's ≤3.9 mmol/L threshold does not appear; the models are multicellular human islet models (>500 α-, β- and δ-cells), not 'modelling of δ-cells', and their quantitative conclusion (23% of high-glucose suppression of glucagon) is excitatory, not inhibitory. (LLM, conf=0.80)
Checked by a reasoning model — may be wrong.
- Not checked yetcites Miranda et al., 2022
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a setting of T1D and late-stage (insulin-deficient) T2D, hypoglycemia is the most common complication of intensive glucose-lowering therapy using insulin analogues and/or secretagogues (i.e., sulfonylureas and glinides; T2D only) ( Cryer, 2002 ).”
What the sources say
- Supportedcites Cryer, 2002 source
The paper's thesis (The Barrier of Hypoglycaemia, p. 1; Perspective, p. 10) is that iatrogenic hypoglycaemia is 'the limiting factor in the glycaemic management of diabetes', driven by the interplay of insulin excess and compromised counterregulation in Type I and advanced Type II diabetes (Clinical Risk Factors, p. 9). Its frequency data support the 'most common' paraphrase: in T1D, glucose <3.3 mmol/l about 10% of the time, ~2 symptomatic episodes a week and ~1 severe episode a year (p. 2), and in T2D hypoglycaemia becomes progressively more frequent and limiting 'as patients approach the insulin deficient end of the spectrum' (p. 8-9). The therapy named is also in our copy — the pharmacokinetic imperfections of 'even the most rapid-acting insulin analogues' (p. 2) and excessive/ill-timed 'insulin secretagogue' doses among the conventional risk factors, with UKPDS sulfonylurea-related major hypoglycaemia (pp. 8-9). Note the source adds that overall rates are roughly tenfold lower in T2D than T1D and lower still on oral agents, which qualifies but does not contradict the claim as restricted to late-stage insulin-deficient T2D. (LLM, conf=0.80)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“they support the conclusions that 1) suppression of SST secretion from islet δ-cells acts as a permissive signal for counterregulatory glucagon release, and 2) this permissive signal may be compromised in T1D and advanced T2D ( Vergari et al., 2020 ).”
What the sources say
- Partly supportedcites Vergari et al., 2020 sourceExperimental — accuracy not yet measured
Our copy supports the first limb: the Discussion/Abstract passage (p. null, 'Abstract'/model section) states that 'the stimulation of glucagon secretion is secondary to the suppression of Sst secretion, resulting in removal of paracrine suppression of α-cells', with dapagliflozin and the SSTR2 antagonist CYN154806 reversing glucose-induced inhibition of glucagon (Fig. 2h), and the abstract's proposal that correcting Sst defects restores 'counter-regulatory glucagon secretion'. The second limb is only partly covered: the paper's diabetes data are in hyperglycaemic Fh1βKO mice and islets from T2DM donors (increased basal Sst at 1 mM glucose, >75% and ~65% reductions in glucagon secretion, relieved by CYN154806), i.e. type 2, and our copy contains no type 1 diabetes data or T1D statement — the general background sentence 'In diabetes, increased somatostatinergic signalling leads to defective counter-regulatory glucagon secretion' is credited to another work (ref. 3, Yue et al. 2012, STZ-induced diabetic rats). The T1D component of the claim is therefore not supported by this source. (LLM, conf=0.78)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with the observation of elevated SST secretion at 1 mmol/L glucose, application of a SST receptor 2 antagonist (SSTR2a, CYN154806) in Fh1βKO islets stimulated glucagon release by 143% ± 11% compared to 13% ± 14% in control mouse islets ( Vergari et al., 2020 ).”
What the sources say
- Supportedcites Vergari et al., 2020 source
The passage labeled Abstract reports that, at 1 mM glucose, CYN154806 increased glucagon secretion by 143±11% in Fh1βKO mouse islets versus 13±14% in controls. It also identifies CYN154806 as an SSTR2 antagonist and reports elevated somatostatin secretion in the Fh1βKO islets. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, α-cells fail to meet this demand, becoming increasingly “blind” (unresponsive) to hypoglycemia with longer duration diabetes and progressive insulin deficiency ( Madsbad et al., 1982 ; Cryer, 2005 ; Siafarikas et al., 2012 ; Zenz et al., 2018 ).”
What the sources say
- Not checked yetcites Madsbad et al., 1982
- Not checked yetcites Cryer, 2005
- Partly supportedcites Siafarikas et al., 2012 sourceExperimental — accuracy not yet measured
The Results (Counterregulatory response; page unavailable) show a reduced glucagon response to hypoglycemia in adolescents with type 1 diabetes and an association with longer diabetes duration. But the Results (Regression analysis; page unavailable) found no significant correlation with fasting or stimulated C-peptide, so the asserted link to progressive insulin deficiency is not established by this study. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
72 more claims · 6 with their cited sources checked
Create a free account to see all 124 claims and to verify the 123 references still open.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 16
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“In rodents, insulin and glucagon are inhibited by SSTR2 and SSTR5, respectively ( Strowski et al., 2000 ).”
“by distinct SSTR subtypes (SSTR5 for insulin and SSTR2 for glucagon) in rodents ( Strowski et al., 2000 ).”
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“%) glycemic control in patients with longstanding T2D largely negated the cardiovascular bene fi ts of intensive glycemic management (Patel et al., 2005; ADVANCE Collaborative Group et al., 2008; Duckworth et al., 2009).”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“GLP-1 reduces postprandial glucose excursions by stimulating insulin release from pancreatic β -cells, inhibiting gastric motility, and promoting satiety (Baggio and Drucker, 2007).”
Background6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403 · cited 1×
“To offset this risk, clinical practice guidelines recommend a temporary relaxation in glycemic targets upon self-report of one or more severe hypoglycemic events (ADAPP, 2022), which typically precludes the maintenance of normal HbA1C levels in adults living with diabetes (Zammitt and Frier, 2005).”
BackgroundReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“People with obesity and/or T2D have impaired incretin release (Toft-Nielsen et al., 2001; Vilsbøll et al., 2001) and/or function (Nauck et al., 1986; Muscelli et al., 2008), and GLP-1-targeted therapies offer effective management of body weight and blood glucose levels, with underlying improvements…”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Cited by
Applying technologies to simplify strategies for exercise in type 1 diabetes
Perkins, B. A., Turner, L. V., & Riddell, M. C. (2024) · Diabetologia · doi:10.1007/s00125-024-06229-x · Cited by 25
Self-citationHill, T. G., & Hill, D. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074070 · Cited by 26
“The use of SSTR2a’s to restore glucagon counter regulation in diabetes has been recently reviewed by Hoffman and colleagues [257].”
BackgroundEngström, K. S., Nilsson, Å. L., Ofori, J. K., Wierup, N., Bacos, K., & Ling, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-21595-1 · Cited by 7
Gao, R., Acreman, S., Dou, H., Ma, J., MIRANDA, C. A., Zhao, R., Dickerson, M. T., Tarasov, A. I., Zou, Q., Gironella-Torrent, M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01422-7 · Cited by 5
“These findings have therapeutic implications and reinforce previous arguments in favour of SSTR2 antagonists as a means of preventing severe hypoglycaemia in patients with insulin-treated diabetes 68 .”
D’Souza, N. C., Aiken, J., Hoffman, E. G., ATHERLEY, S. C., Champsi, S., ALEALI, N., Shakeri, D., El-Zahed, M., Akbarian, N., Nejad-Mansouri, M., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1302015 · Cited by 8
Self-citation
Metadata
- Authors
- Hoffman, E. G., D’Souza, N. C., Liggins, R. T., & Riddell, M. C.
- Affiliations
- York University (CA)
- Corresponding author
- Hoffman, Emily G.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2024-01-17
- Volume
- 14
- Pages
- 1295639-1295639
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10829877
- OpenAlex
- W4390940962
- Cited by
- 13
- References
- 117
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 3
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Juvenile Diabetes Research Foundation Canada
- Government of Canada
- Natural Sciences and Engineering Research Council of Canada (261306)
- Canadian Glycomics Network
- Breakthrough T1D Canada (2-PAR-2023-1312-A-N)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- somatostatin receptor 2, somatostatin, type 1 diabetes, hypoglycemia, pancreatic islets, alpha cells, pancreatic beta cells, glucose homeostasis, cAMP signaling, islet hormones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes. https://app.cochat.ai/papers/10.3389/fphar.2023.1295639
- The paper
- Hoffman, E. G., D’Souza, N. C., Liggins, R. T., & Riddell, M. C. (2024). Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1295639
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.